Stemline Therapeutics Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Stemline Therapeutics (STML) Misses Q2 EPS by 17c
August 10, 2015 5:08 PM EDTStemline Therapeutics (NASDAQ: STML) reported Q2 EPS of ($0.58), $0.17 worse than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.
... More